Company Focus
Novartis
Latest Novartis News
Pharmaceutical
A US district court judge has found that the Department of Health and Human Services (HHS) must preapprove the use of 340B rebate models before they can be implemented. 19 May 2025
Related News
Insights
Company Spotlight
A Munich, Germany-based biotech company in the antibody drug conjugate (ADC) space.
Latest News & Features of interest to Novartis
Pharmaceutical
Chinese biotech Minghui Pharmaceutical has sold certain rights to its experimental cancer drug MHB088C to Qilu Pharmaceutical in a licensing deal worth up to $177 million. 12 May 2025
Pharmaceutical
Denmark, oncology-based Pharmacosmos today announced that it has assumed the worldwide rights, excluding select Asia-Pacific territories, to the investigational oncology asset lerociclib. 12 May 2025
Biotechnology
US biotech PTC Therapeutics released mixed new data on its Phase II trial of PCT187 (votoplam) in Huntington’s disease. UK biotech Alchemab signed a deal for its amyotrophic lateral sclerosis (ALS) drug ATLX-1282 with Eli Lilly worth up to $415 million. Danish drugmaker Genmab posted first-quarter results, in line with expectations. US precision oncology firm Boundless Bio released an update on its novel kinesin program including BBI-825. 11 May 2025
Biotechnology
US precision oncology company Boundless Bio has announced financial results and business highlights for the fiscal quarter ended March 31, 2025. 10 May 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Pharmaceutical
US pharma major Eli Lilly yesterday announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide. 9 May 2025
Biotechnology
Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, has raised $65 million in a Series A funding round. 9 May 2025
Pharmaceutical
UK pharma major AstraZeneca has suffered a setback in its legal fight to block the US government's efforts to lower prescription drug prices, after a federal appeals court dismissed its challenge to Medicare’s negotiation powers. 9 May 2025
Biotechnology
Positive high-level results have been presented by AstraZeneca from the POTOMAC Phase III trial. 9 May 2025
Biotechnology
Genmab posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties and increasing sales of its lymphoma therapy Epkinly (epcoritamab). Earnings before interest and taxes rose to $188 million, up from $116 million a year earlier. 9 May 2025
Latest In Brief for Novartis
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Ones To Watch News
US clinical-stage biotech Vigil Neuroscience saw its share price skyrocket more than 240% to $7.89 pre-market, on the news that French pharma major Sanofi had made a takeover bid for the company. 22 May 2025
30 April 2025
28 April 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze